GGrantIndex
Sort

64,565 grants matching drug discovery

Sphingolipids, Diabetes, and Cardiovascular Disease

$534,613
Rozenn Lemaitre · University Of Washington · R01 · FY2015 · DK

INTEGRATIVE MODEL OF SUBCELL PROCESSES: APPL TO SYNAPTIC ACT & PHARM DISCOVERY

$534,591
James A McCammon · University Of California, San Diego · P41 · FY2007 · RR

Genetic and Molecular Basis of Longevity

$534,502
Gary B. Ruvkun · Massachusetts General Hospital · R01 · FY2011 · AG

Selective Inhibitors of Pro-Ferroptotic Lipoxygenases - Next Generation Radiomitigators

$534,477
Valerian E Kagan · University Of Pittsburgh At Pittsburgh · U01 · FY2021 · AI

Training in Pharmacological Sciences

$534,450
David E. Golan · Harvard Medical School · T32 · FY2025 · GM

Symbiosis and Chemical Diversity Generation

$534,448
Eric W Schmidt · University Of Utah · R35 · FY2018 · GM

Discovery of 12/15-lipoxygenase therapeutics for Alzheimer's disease

$534,417
Theodore R Holman · University Of California Santa Cruz · R01 · FY2022 · AG

Molecular Pathways of Pain Generation in Osteoarthritis

$534,402
Anne-Marie Malfait · Rush University Medical Center · R01 · FY2025 · AR

Rational Design of antivrials targeted to HIV-1 capsid

$534,400
Asim K Debnath · New York Blood Center · R01 · FY2010 · AI

Drug Discovery and Development

$534,392
Paul D. Robbins · Mayo Clinic Rochester · P01 · FY2023 · AG

Mechanisms of DNA and RNA transactions

$534,384
Stewart H Shuman · Sloan-Kettering Inst Can Research · R35 · FY2018 · GM

Large-Scale Discovery of Functional Genetic Variation in Rhesus Macaques

$534,371
Jeffrey A Rogers · Baylor College Of Medicine · R24 · FY2014 · OD

Targeting Integrin Signaling in Atherosclerosis

$534,347
Darren G Woodside · Texas Heart Institute · R33 · FY2025 · HL

Inhibition of hepatic (V)LDL production by a novel antagonist of carboxyl esterase 1

$534,330
Stephen A Duncan · Medical University Of South Carolina · R01 · FY2025 · DK

Coupling Epitranscriptomics to Molecular Disease Mechanisms and Nucleic Acid Therapeutics in Persistent Residual HIV Infection

$534,319
Keith Thomas Gagnon · Wake Forest University Health Sciences · R61 · FY2024 · AI

Clinical Pharmacology, Drug Action and Pharmacogenetics

$534,314
Radojka Savic · University Of California, San Francisco · T32 · FY2024 · GM

Intervention Core for the Dietary Biomarkers Development Center at Harvard University

$534,194
Frank M Sacks · Harvard School Of Public Health · U2C · FY2021 · DK

HTS for Direct Targeting of the Transcription Factor MITF

$534,190
Thomas J. Kodadek · Scripps Florida · R01 · FY2016 · CA

APOBEC3 STRUCTURAL STUDIES

$534,174
Reuben S Harris · University Of Minnesota · R01 · FY2019 · GM

Discovery and development of novel glycine transporter-2 inhibitors for the treatment of neuropathic pain

$534,125
Christopher L. Cioffi · Albany College Of Pharmacy · R01 · FY2019 · DA

Resources for Teleost Gene Duplicates and Human Disease

$534,097
John Harvey Postlethwait · University Of Oregon · R01 · FY2006 · RR

Drosophila Genomics Resource Center

$534,063
Peter T Cherbas · Trustees Of Indiana University · P40 · FY2014 · OD

Resource to Advance Pediatrics and HIV Prevention Science (RAPPS): Quality Assurance/Quality Control (QA/QC) Support

$534,007
Peter Silvera · Advanced Bioscience Laboratories, Inc. · N01 · FY2024 · AI

Effect of inflammation on JAK2 mutant evolution in the hematopoietic system: mathematical models and experiments

$533,981
Angela Goffredo Fleischman · University Of California-Irvine · R37 · FY2023 · CA

Structural Analysis of Macromolecular Assemblies

$533,969
Joachim Frank · Columbia University Health Sciences · R01 · FY2016 · GM